Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-06-07

Schrödinger, Inc.

Schrödinger develops physics-based molecular discovery software and cloud workflows for biopharma and materials customers, while also earning partner-led drug discovery revenue and upside.

ai biotech cloud healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From modeling vendor to discovery operating layer

The core upside is a transition from lumpy licenses to a cleaner hosted workflow business with AI-assisted throughput and partner-validated discovery optionality. The stock works if usage, renewals, and workflow ownership prove it captures more of the discovery process, not just a point-tool budget.

Analysis

Thesis

Schrödinger can compound into a higher-quality discovery operating layer if hosted licensing converts its installed pharma base into durable recurring revenue and if Bunsen lifts usage per program; the upside is a cleaner software-plus-partner model, not a return to balance-sheet-heavy biotech risk.

Last Economy Alignment

Cheaper cognition and compute should expand computational discovery and make LiveDesign more valuable as a shared R&D workspace, while usage-based pricing limits classic seat compression. The cap is that large pharma can internalize more of the stack and alternative AI tools can bypass parts of the workflow.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.5x (from 5 most recent analyses)

Reasoning

The upside is mostly a quality rerating plus steady revenue compounding. Hosted delivery should make sales stickier and more legible, Bunsen can raise usage per discovery program, and collaborations add option value. I keep the multiple below true platform leaders because the company still has to prove renewal strength, pricing durability, and that AI agents deepen workflow control rather than route around it.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is validation, not solvency. Schrödinger must prove that hosted ACV, Bunsen, and workflow control translate into durable revenue quality and better margins before the market will pay up; if customers treat it as useful science infrastructure rather than the operating layer, the upside compresses quickly.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material company-specific filing or press release appeared in the last 10 days; the thesis still rests on the May 5, 2026 quarter and guidance.
Investor focus has shifted from reported revenue noise toward the summer 2026 Bunsen early-access window and proof of hosted monetization.
The next dated governance checkpoint remains the June 22, 2026 annual meeting, including the proposed 3.0 million-share incentive-plan increase.

Thesis update

No material change. Recent evidence reinforced that the gating issue is commercial proof of hosted and AI workflow monetization, not scientific relevance.

Forecast update

The valuation now leans less on a large rerating and more on steady ACV-to-revenue conversion, reflecting clearer 2028 targets, ratable revenue timing, and still-unproven go-to-market scaling.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.51

It sits where cheaper compute and AI can create more experiments and more decisions, and it already owns a real workflow hub in LiveDesign. But it does not own the whole stack, so big pharma or cheaper AI tools could keep the science while routing around the interface.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$20.88

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research